mw03, you're right mate. IGF-1 is being tested because it is already approved by the FDA for growth related conditions. It is definitely a competitor.
There are a couple of reasons why nnz-2566 walks all over IGF-1 though.
1. nnz-2566 is orally available while IGF-1 requires injections.
2. IGF-1 cannot be used with older patients in all diseases as it will promote excessive growth, while nnz-2566 does not have that issue.
- Forums
- ASX - By Stock
- NEU
- Wider autism efficacy potential for nnz-2566
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.75%
!
$14.57

Wider autism efficacy potential for nnz-2566, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.57 |
Change
0.390(2.75%) |
Mkt cap ! $1.806B |
Open | High | Low | Value | Volume |
$14.36 | $14.75 | $14.36 | $6.628M | 454.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 424 | $14.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.57 | 775 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 109 | 14.550 |
8 | 491 | 14.540 |
10 | 803 | 14.530 |
6 | 1246 | 14.520 |
5 | 1272 | 14.510 |
Price($) | Vol. | No. |
---|---|---|
14.560 | 400 | 8 |
14.570 | 345 | 3 |
14.580 | 1410 | 10 |
14.590 | 1259 | 7 |
14.600 | 1865 | 8 |
Last trade - 13.31pm 10/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |